CLINICAL STUDIES
Aiming to improve the body’s repair mechanisms by harnessing its own regenerative capacity, Recardio has now proceeded with the clinical evaluation of its lead candidate dutogliptin in cardiovascular indications to the global pivotal Phase 3 study. Other development programs are in earlier clinical and preclinical stage.
Phase 1 Study (REC-DUT-001)
The Phase 1 study of parenteral application of dutogliptin evaluated the PK/PD and safety in healthy volunteers.
Phase 2B Study in AMI (REC-DUT-002)
The global multicenter, randomized, double blind, placebo controlled, parallel group study evaluated the safety and effectiveness of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.
Phase 3 Study in AMI (HEAL-MI, REC-DUT-003)
The global pivotal multicenter, randomized, double blind, placebo controlled, parallel group study is evaluating the safety and effectiveness of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction in a large population.
Phase 2B Study in CHF (REC-DUT-003)
The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with advanced heart failure.